ORIC - Oric Pharmaceuticals, Inc.

QQQ $ 435.98 $ 8.58 (2.01 %)

DIA $ 386.87 $ 4.54 (1.19 %)

SPY $ 511.25 $ 6.26 (1.24 %)

TLT $ 89.88 $ 0.90 (1.01 %)

GLD $ 212.97 $ -0.17 (-0.08 %)

Previous Close

$ 9.71

Open

$ 10.03

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 9.50 - $ 10.03

52 Week Range

$ 4.90 - $ 16.65

Volume

277,183

Average Volume

Market Cap

499.59M

Beta (5Y Monthly)

$ 1.08

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	03-11-2024	12-31-2023	10-K
2	11-06-2023	09-30-2023	10-Q
3	08-10-2023	06-30-2023	10-Q
4	05-08-2023	03-31-2023	10-Q
5	03-16-2023	12-31-2022	10-K
6	11-07-2022	09-30-2022	10-Q
7	08-11-2022	06-30-2022	10-Q
8	05-09-2022	03-31-2022	10-Q
9	03-21-2022	12-31-2021	10-K
10	11-08-2021	09-30-2021	10-Q
11	08-10-2021	06-30-2021	10-Q
12	05-06-2021	03-31-2021	10-Q
13	03-23-2021	12-31-2020	10-K
14	11-05-2020	09-30-2020	10-Q
15	08-05-2020	06-30-2020	10-Q
16	05-20-2020	03-31-2020	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

ORIC Pharmaceuticals Announces First Patie...
04/15/2024 20:16:07

Initiated multiple Phase 1b expansion cohorts to determine the RP2D of ORIC-114 in NSCLC patients with EGFR exon 20, HER2 exon ...

ORIC Pharmaceuticals Presents Preclinical ...
04/08/2024 12:15:21

ORIC-944, a potent and selective allosteric PRC2 inhibitor, demonstrates superior preclinical drug properties and longer clinic...

JP Morgan Maintains Overweight on ORIC Pha...
03/27/2024 14:40:45

JP Morgan analyst Anupam Rama maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Overweight and lowers the price target fro...

Micron To Rally Around 134%? Here Are 10 T...
03/21/2024 13:15:39

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

HC Wainwright & Co. Maintains Buy on ORIC ...
03/21/2024 10:15:52

HC Wainwright & Co. analyst Robert Burns maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and raises the price ta...

these-analysts-revise-their-forecasts-on-oric-pharmaceuticals-after-q4-results

These Analysts Revise Their Forecasts On O...
03/12/2024 16:55:50

ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) reported a loss for the fourth quarter on Monday.

Oppenheimer Maintains Outperform on ORIC P...
03/12/2024 16:49:39

Oppenheimer analyst Matthew Biegler maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Outperform and raises the price targ...

Wedbush Reiterates Outperform on ORIC Phar...
03/12/2024 12:22:01

Wedbush analyst David Nierengarten reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Outperform and maintains $20 price t...

Baird Maintains Outperform on ORIC Pharmac...
03/12/2024 12:06:18

Baird analyst Colleen Kusy maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Outperform and lowers the price target from $...

ORIC Pharmaceuticals Q4 EPS $(0.49), Inline
03/11/2024 20:22:42

ORIC Pharmaceuticals (NASDAQ:ORIC) reported quarterly losses of $(0.49) per share which met the analyst consensus estimate. Thi...

Wedbush Maintains Outperform on ORIC Pharm...
03/01/2024 13:43:39

Wedbush analyst David Nierengarten maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Outperform and raises the price targe...

why-butterfly-network-shares-are-trading-lower-by-22-here-are-other-stocks-moving-in-thursdays-mid-day-session

Why Butterfly Network Shares Are Trading L...
02/29/2024 19:00:01

Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed four...

Hormel Foods Reports Upbeat Earnings, Join...
02/29/2024 16:30:35

U.S. stocks were higher, with the Nasdaq Composite gaining around 50 points on Thursday.

Cantor Fitzgerald Initiates Coverage On OR...
02/23/2024 18:42:16

Cantor Fitzgerald analyst Prakhar Agrawal initiates coverage on ORIC Pharmaceuticals (NASDAQ:ORIC) with a Overweight rating.

ORIC Pharmaceuticals Announces $125M Priva...
01/22/2024 13:34:17

Funding from new and existing investors including Viking Global Investors, Commodore Capital, Frazier Life Sciences, Venrock He...

ORIC Announces Initial Phase 1b Data For O...
01/08/2024 13:44:33

Oric Pharmaceuticals Inc Files For Shelf O...
12/15/2023 21:35:07

- SEC Filing

Where ORIC Pharmaceuticals Stands With Ana...
12/13/2023 17:00:16

HC Wainwright & Co. Maintains Buy on ORIC ...
12/13/2023 11:28:57

HC Wainwright & Co. analyst Robert Burns maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and lowers the price ta...

$initial-phase-1-dose-escalation-data-for-oric-533-in-relapsedrefractory-multiple-myeloma-demonstrates-clinical-activity-and-strong-safety-profile-supporting-potential-for-combination-development-at-the-65th-american-society-of-hematology-annual-meeting$

Initial Phase 1 Dose Escalation Data For O...
12/11/2023 17:05:47

Preliminary evidence of clinical antimyeloma activity, including reduction in paraprotein, demonstrated in multiple patients Cl...